93 related articles for article (PubMed ID: 16624245)
1. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates.
Ghosh P; Moitra K; Maki N; Dey S
Arch Biochem Biophys; 2006 Jun; 450(1):100-12. PubMed ID: 16624245
[TBL] [Abstract][Full Text] [Related]
2. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
Maki N; Dey S
Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein.
Maki N; Moitra K; Ghosh P; Dey S
J Biol Chem; 2006 Apr; 281(16):10769-77. PubMed ID: 16505485
[TBL] [Abstract][Full Text] [Related]
6. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Maki N; Hafkemeyer P; Dey S
J Biol Chem; 2003 May; 278(20):18132-9. PubMed ID: 12642584
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
9. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
[TBL] [Abstract][Full Text] [Related]
10. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
[TBL] [Abstract][Full Text] [Related]
11. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
Qu Q; Russell PL; Sharom FJ
Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
[TBL] [Abstract][Full Text] [Related]
12. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
13. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Arch Biochem Biophys; 2000 Nov; 383(1):91-8. PubMed ID: 11097180
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.
Tombline G; Donnelly DJ; Holt JJ; You Y; Ye M; Gannon MK; Nygren CL; Detty MR
Biochemistry; 2006 Jul; 45(26):8034-47. PubMed ID: 16800628
[TBL] [Abstract][Full Text] [Related]
15. Catalytic mechanism of P-glycoprotein.
Senior AE
Acta Physiol Scand Suppl; 1998 Aug; 643():213-8. PubMed ID: 9789563
[TBL] [Abstract][Full Text] [Related]
16. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).
Ambudkar SV; Kim IW; Sauna ZE
Eur J Pharm Sci; 2006 Apr; 27(5):392-400. PubMed ID: 16352426
[TBL] [Abstract][Full Text] [Related]
17. Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
Mandal D; Moitra K; Ghosh D; Xia D; Dey S
Biochemistry; 2012 Apr; 51(13):2852-66. PubMed ID: 22360349
[TBL] [Abstract][Full Text] [Related]
18. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Nagy H; Goda K; Fenyvesi F; Bacsó Z; Szilasi M; Kappelmayer J; Lustyik G; Cianfriglia M; Szabó G
Biochem Biophys Res Commun; 2004 Mar; 315(4):942-9. PubMed ID: 14985103
[TBL] [Abstract][Full Text] [Related]
19. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes.
Fong WF; Wan CK; Zhu GY; Chattopadhyay A; Dey S; Zhao Z; Shen XL
Planta Med; 2007 Mar; 73(3):212-20. PubMed ID: 17318783
[TBL] [Abstract][Full Text] [Related]
20. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
